Asthma: Comprehensive Clinical Monograph
Last updated: 06/17/2025
Asthma is a heterogeneous disease characterized by chronic airway inflammation and defined by a history of respiratory symptoms (wheezing, shortness of breath, chest tightness, cough). Symptom intensity and expiratory flow characteristically vary over time.
Definitions
- Asthma: Chronic airway inflammation with variable respiratory symptoms and variable expiratory airflow.
- Acute asthma exacerbation: Reversible worsening of features developing over a short period; can progress to life-threatening status.
Epidemiology (US)
Allergic: Childhood
Nonallergic: > 40 years
Risk Factors & Triggers
Allergic (Extrinsic)
- • Cardinal Risk: Atopy
- • Pollen (seasonal)
- • Dust mites & Mold spores
- • Domestic animals
- • Occupational allergens (e.g., flour dust)
Nonallergic (Intrinsic)
- • Viral RTIs (especially in childhood)
- • Extreme cold weather
- • Physical exertion (laughter, exercise)
- • GERD (Concurrent occurrence)
- • Chronic sinusitis/rhinitis
- • Drugs: Aspirin, NSAIDs, Beta blockers
- • Stress & Tobacco smoke
Occupational Asthma Subtypes
- Sensitizer-induced: IgE-mediated (flour, animal proteins, diisocyanates).
- Irritant-induced: Acute inhalation injury or repeated exposure (vapors, gas).
- Reactive Airways Dysfunction Syndrome (RADS): Sudden onset within 24h of high concentration corrosive exposure.
Pathophysiology
The Three Components
1. Bronchial Inflammation (Th2-cell Driven)
Antigen inhalation → Th2 overexpression → Cytokine release (IL-3, IL-4, IL-5, IL-13) → B-cell IgE production → Eosinophil activation → Submucosal edema & Smooth muscle contraction → Bronchiolar collapse.
2. Bronchial Hyperresponsiveness
Increased parasympathetic tone and exaggerated response to triggers.
3. Endobronchial Obstruction Mechanisms
- Reversible bronchospasm
- Increased mucus production (Goblet cell hyperplasia)
- Mucosal edema and leukocyte infiltration
- Smooth muscle hypertrophy
Samter Triad (Aspirin-Exacerbated Respiratory Disease)
1. Asthma symptoms (via COX-1 inhibition → ↑ Leukotrienes)
2. Chronic rhinosinusitis with nasal polyposis
3. Aspirin/NSAID sensitivity
Diagnostics & Biomarkers
Spirometry (Gold Standard)
Expiratory airflow limitation (FEV1 and FEV1/FVC ratio) below Lower Limit of Normal (LLN).
↑ FEV1 of ≥ 12% and ≥ 200 mL in response to bronchodilator or 4 weeks of ICS.
Methacholine challenge: ↓ FEV1 ≥ 20% from baseline (high sensitivity, low specificity).
Additional Biomarkers & Findings
Sputum Analysis
- • Curschmann spirals: Spiral mucus plugs.
- • Charcot-Leyden crystals: Eosinophilic inflammation.
- • Creola bodies: Desquamated epithelial aggregates.
Blood/Exhaled Markers
- • FeNO: Marker of eosinophilic/T2 inflammation.
- • Blood Eosinophils: Elevated count supports diagnosis.
- • Total/Specific IgE: Elevated in allergic phenotypes.
Stepwise Pharmacotherapy (Age ≥ 12)
GINA 2025 vs NAEPP 2020 Guidelines
| Step | GINA 2025 Preferred | NAEPP 2020 |
|---|---|---|
| Step 1 | PRN low-dose Budesonide/Formoterol (Symptoms < 4-5 days/wk) | PRN Albuterol (Intermittent) |
| Step 2 | (Same as Step 1) or daily low-dose ICS | Daily low-dose ICS + PRN SABA |
| Step 3 | Scheduled & PRN low-dose ICS/Formoterol | Scheduled med-dose ICS-Formoterol OR low-dose ICS + PRN SABA |
| Step 4 | Scheduled med-dose Budesonide/Formoterol + PRN same | Scheduled med-dose ICS/Formoterol + PRN same |
| Step 5 | High-dose ICS/LABA + add-on (LAMA/Biologics) | High-dose ICS/LABA + consider Biologics |
Additional Asthma Drugs
Biologics
Omalizumab: Anti-IgE (Refractory severe allergic).
Dupilumab: Anti-IL-4Rα (Mod-severe eosinophilic).
Mepolizumab/Benralizumab: Anti-IL-5 (Refractory eosinophilic).
Leukotriene Modifiers
Zileuton/Montelukast: Inhibit 5-lipoxygenase. Indicated for exercise-induced or aspirin-induced asthma.
Special Populations
Asthma in Pregnancy
Asthma symptoms may worsen, improve, or stay unchanged. Poor management increases risk of preeclampsia, premature birth, and congenital abnormalities.
- Inhalation treatments are preferred.
- Monthly monitoring is recommended.
- Management follows standard stepwise approach.
Pediatrics (< 5 Years)
Often underdiagnosed due to difficulty performing spirometric maneuvers.
- Glucocorticoid-containing regimens preferred as initial therapy.
- Nebulizers may be required due to inhaler technique difficulties.
Lifestyle & Prevention
Provide written action plans and tools for self-monitoring (PEF). Encourage physical activity and diets rich in fruits/vegetables (Mediterranean/DASH). Ensure immunizations (Influenza, COVID-19, Pneumococcal).
© 2025-2026 FreeMedsite Clinical Editorial Board. Derived from GINA 2025/2026 and NAEPP 2020 Guidelines. For professional use only.
0 Comments